nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Carboplatin—urinary bladder cancer	0.225	0.277	CbGbCtD
Pyrazinamide—XDH—Cisplatin—urinary bladder cancer	0.192	0.236	CbGbCtD
Pyrazinamide—AOX1—Methotrexate—urinary bladder cancer	0.144	0.177	CbGbCtD
Pyrazinamide—XDH—Doxorubicin—urinary bladder cancer	0.129	0.158	CbGbCtD
Pyrazinamide—CYP3A4—Thiotepa—urinary bladder cancer	0.0475	0.0584	CbGbCtD
Pyrazinamide—CYP1A2—Fluorouracil—urinary bladder cancer	0.0295	0.0362	CbGbCtD
Pyrazinamide—CYP1A2—Etoposide—urinary bladder cancer	0.0246	0.0302	CbGbCtD
Pyrazinamide—CYP3A4—Etoposide—urinary bladder cancer	0.0129	0.0158	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00878	0.0108	CbGbCtD
Pyrazinamide—XDH—prostate gland—urinary bladder cancer	0.00523	0.128	CbGeAlD
Pyrazinamide—CYP1A2—urine—urinary bladder cancer	0.00508	0.124	CbGeAlD
Pyrazinamide—CYP3A4—urine—urinary bladder cancer	0.00367	0.0897	CbGeAlD
Pyrazinamide—XDH—renal system—urinary bladder cancer	0.00356	0.087	CbGeAlD
Pyrazinamide—AOX1—prostate gland—urinary bladder cancer	0.00332	0.0811	CbGeAlD
Pyrazinamide—XDH—female reproductive system—urinary bladder cancer	0.00285	0.0696	CbGeAlD
Pyrazinamide—XDH—Purine catabolism—GPX1—urinary bladder cancer	0.00281	0.0505	CbGpPWpGaD
Pyrazinamide—AOX1—seminal vesicle—urinary bladder cancer	0.00281	0.0686	CbGeAlD
Pyrazinamide—XDH—vagina—urinary bladder cancer	0.00258	0.063	CbGeAlD
Pyrazinamide—AOX1—renal system—urinary bladder cancer	0.00226	0.0553	CbGeAlD
Pyrazinamide—Dysuria—Valrubicin—urinary bladder cancer	0.00223	0.0246	CcSEcCtD
Pyrazinamide—AOX1—urethra—urinary bladder cancer	0.00222	0.0543	CbGeAlD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.00207	0.0371	CbGpPWpGaD
Pyrazinamide—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00193	0.0346	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00188	0.0338	CbGpPWpGaD
Pyrazinamide—Hepatomegaly—Thiotepa—urinary bladder cancer	0.00186	0.0205	CcSEcCtD
Pyrazinamide—AOX1—female reproductive system—urinary bladder cancer	0.00181	0.0443	CbGeAlD
Pyrazinamide—AOX1—vagina—urinary bladder cancer	0.00164	0.04	CbGeAlD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.00161	0.0289	CbGpPWpGaD
Pyrazinamide—XDH—Oxidative Stress—NQO1—urinary bladder cancer	0.00159	0.0286	CbGpPWpGaD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.00157	0.0282	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Valrubicin—urinary bladder cancer	0.00154	0.017	CcSEcCtD
Pyrazinamide—Malaise—Valrubicin—urinary bladder cancer	0.0015	0.0165	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Gemcitabine—urinary bladder cancer	0.00143	0.0158	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Thiotepa—urinary bladder cancer	0.00142	0.0157	CcSEcCtD
Pyrazinamide—Myalgia—Valrubicin—urinary bladder cancer	0.00141	0.0156	CcSEcCtD
Pyrazinamide—Discomfort—Valrubicin—urinary bladder cancer	0.0014	0.0154	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Thiotepa—urinary bladder cancer	0.00134	0.0148	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Cisplatin—urinary bladder cancer	0.00134	0.0148	CcSEcCtD
Pyrazinamide—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0013	0.0234	CbGpPWpGaD
Pyrazinamide—XDH—Nucleotide metabolism—TYMP—urinary bladder cancer	0.00127	0.0228	CbGpPWpGaD
Pyrazinamide—CYP1A2—renal system—urinary bladder cancer	0.00124	0.0303	CbGeAlD
Pyrazinamide—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00123	0.0136	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Etoposide—urinary bladder cancer	0.00122	0.0135	CcSEcCtD
Pyrazinamide—XDH—Oxidative Stress—SOD2—urinary bladder cancer	0.00122	0.022	CbGpPWpGaD
Pyrazinamide—XDH—Oxidative Stress—GPX1—urinary bladder cancer	0.00117	0.021	CbGpPWpGaD
Pyrazinamide—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00115	0.0207	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00112	0.0123	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Cisplatin—urinary bladder cancer	0.00111	0.0123	CcSEcCtD
Pyrazinamide—XDH—Purine metabolism—GPX1—urinary bladder cancer	0.00108	0.0194	CbGpPWpGaD
Pyrazinamide—Body temperature increased—Valrubicin—urinary bladder cancer	0.00107	0.0118	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Mitomycin—urinary bladder cancer	0.00106	0.0117	CcSEcCtD
Pyrazinamide—AOX1—lymph node—urinary bladder cancer	0.00106	0.0259	CbGeAlD
Pyrazinamide—Blood uric acid increased—Cisplatin—urinary bladder cancer	0.00105	0.0116	CcSEcCtD
Pyrazinamide—Malaise—Mitomycin—urinary bladder cancer	0.00103	0.0114	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Etoposide—urinary bladder cancer	0.00102	0.0113	CcSEcCtD
Pyrazinamide—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00101	0.0181	CbGpPWpGaD
Pyrazinamide—XDH—Nucleotide metabolism—RRM2—urinary bladder cancer	0.000992	0.0178	CbGpPWpGaD
Pyrazinamide—Body temperature increased—Carboplatin—urinary bladder cancer	0.000992	0.011	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Fluorouracil—urinary bladder cancer	0.00099	0.0109	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Etoposide—urinary bladder cancer	0.000963	0.0106	CcSEcCtD
Pyrazinamide—Discomfort—Mitomycin—urinary bladder cancer	0.000962	0.0106	CcSEcCtD
Pyrazinamide—Pruritus—Valrubicin—urinary bladder cancer	0.000959	0.0106	CcSEcCtD
Pyrazinamide—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000935	0.0168	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000914	0.0101	CcSEcCtD
Pyrazinamide—Photosensitivity—Fluorouracil—urinary bladder cancer	0.0009	0.00993	CcSEcCtD
Pyrazinamide—CYP3A4—renal system—urinary bladder cancer	0.000899	0.0219	CbGeAlD
Pyrazinamide—Anorexia—Mitomycin—urinary bladder cancer	0.00089	0.00983	CcSEcCtD
Pyrazinamide—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00089	0.016	CbGpPWpGaD
Pyrazinamide—Vomiting—Valrubicin—urinary bladder cancer	0.000862	0.00951	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Etoposide—urinary bladder cancer	0.000859	0.00949	CcSEcCtD
Pyrazinamide—Rash—Valrubicin—urinary bladder cancer	0.000855	0.00943	CcSEcCtD
Pyrazinamide—Dermatitis—Valrubicin—urinary bladder cancer	0.000854	0.00942	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000824	0.0148	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000822	0.0148	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Mitomycin—urinary bladder cancer	0.000812	0.00896	CcSEcCtD
Pyrazinamide—Nausea—Valrubicin—urinary bladder cancer	0.000805	0.00889	CcSEcCtD
Pyrazinamide—Dysuria—Thiotepa—urinary bladder cancer	0.000772	0.00852	CcSEcCtD
Pyrazinamide—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00077	0.00849	CcSEcCtD
Pyrazinamide—Hepatomegaly—Epirubicin—urinary bladder cancer	0.000749	0.00827	CcSEcCtD
Pyrazinamide—Body temperature increased—Mitomycin—urinary bladder cancer	0.000738	0.00815	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Methotrexate—urinary bladder cancer	0.000733	0.0081	CcSEcCtD
Pyrazinamide—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000722	0.013	CbGpPWpGaD
Pyrazinamide—CYP3A4—female reproductive system—urinary bladder cancer	0.00072	0.0176	CbGeAlD
Pyrazinamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000706	0.0127	CbGpPWpGaD
Pyrazinamide—Hepatomegaly—Doxorubicin—urinary bladder cancer	0.000693	0.00765	CcSEcCtD
Pyrazinamide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000634	0.0114	CbGpPWpGaD
Pyrazinamide—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.000623	0.00688	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Methotrexate—urinary bladder cancer	0.000611	0.00674	CcSEcCtD
Pyrazinamide—Vomiting—Mitomycin—urinary bladder cancer	0.000594	0.00655	CcSEcCtD
Pyrazinamide—Rash—Mitomycin—urinary bladder cancer	0.000589	0.0065	CcSEcCtD
Pyrazinamide—Dermatitis—Mitomycin—urinary bladder cancer	0.000588	0.00649	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Methotrexate—urinary bladder cancer	0.000577	0.00637	CcSEcCtD
Pyrazinamide—XDH—Nucleotide metabolism—TYMS—urinary bladder cancer	0.000574	0.0103	CbGpPWpGaD
Pyrazinamide—Hyperuricaemia—Epirubicin—urinary bladder cancer	0.000571	0.00631	CcSEcCtD
Pyrazinamide—Nausea—Mitomycin—urinary bladder cancer	0.000555	0.00612	CcSEcCtD
Pyrazinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000545	0.00979	CbGpPWpGaD
Pyrazinamide—XDH—Nucleotide metabolism—GPX1—urinary bladder cancer	0.000544	0.00977	CbGpPWpGaD
Pyrazinamide—Blood uric acid increased—Epirubicin—urinary bladder cancer	0.00054	0.00596	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—urinary bladder cancer	0.000529	0.00584	CcSEcCtD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000519	0.00932	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000518	0.0093	CbGpPWpGaD
Pyrazinamide—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.000504	0.00905	CbGpPWpGaD
Pyrazinamide—Blood uric acid increased—Doxorubicin—urinary bladder cancer	0.000499	0.00551	CcSEcCtD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000495	0.00888	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000494	0.00887	CbGpPWpGaD
Pyrazinamide—Arthralgia—Thiotepa—urinary bladder cancer	0.00049	0.00541	CcSEcCtD
Pyrazinamide—Myalgia—Thiotepa—urinary bladder cancer	0.00049	0.00541	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Epirubicin—urinary bladder cancer	0.000482	0.00532	CcSEcCtD
Pyrazinamide—Photosensitivity—Methotrexate—urinary bladder cancer	0.000468	0.00517	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00046	0.00508	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000456	0.00818	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000449	0.00496	CcSEcCtD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000448	0.00805	CbGpPWpGaD
Pyrazinamide—Anorexia—Thiotepa—urinary bladder cancer	0.000448	0.00494	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.000446	0.00492	CcSEcCtD
Pyrazinamide—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000442	0.00795	CbGpPWpGaD
Pyrazinamide—Photosensitivity—Epirubicin—urinary bladder cancer	0.000438	0.00484	CcSEcCtD
Pyrazinamide—Malaise—Gemcitabine—urinary bladder cancer	0.000437	0.00482	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000428	0.00472	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000423	0.00759	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000419	0.00462	CcSEcCtD
Pyrazinamide—Dyspepsia—Thiotepa—urinary bladder cancer	0.000413	0.00456	CcSEcCtD
Pyrazinamide—Myalgia—Gemcitabine—urinary bladder cancer	0.000412	0.00455	CcSEcCtD
Pyrazinamide—Arthralgia—Gemcitabine—urinary bladder cancer	0.000412	0.00455	CcSEcCtD
Pyrazinamide—Decreased appetite—Thiotepa—urinary bladder cancer	0.000408	0.00451	CcSEcCtD
Pyrazinamide—Discomfort—Gemcitabine—urinary bladder cancer	0.000407	0.00449	CcSEcCtD
Pyrazinamide—Malaise—Cisplatin—urinary bladder cancer	0.000407	0.00449	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000405	0.00448	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000405	0.00447	CcSEcCtD
Pyrazinamide—Myalgia—Fluorouracil—urinary bladder cancer	0.000405	0.00447	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000401	0.0072	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000401	0.0072	CbGpPWpGaD
Pyrazinamide—Discomfort—Fluorouracil—urinary bladder cancer	0.0004	0.00442	CcSEcCtD
Pyrazinamide—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000393	0.00707	CbGpPWpGaD
Pyrazinamide—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000389	0.00698	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000387	0.00427	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000387	0.00427	CcSEcCtD
Pyrazinamide—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000386	0.00693	CbGpPWpGaD
Pyrazinamide—Myalgia—Cisplatin—urinary bladder cancer	0.000384	0.00424	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000384	0.00423	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00038	0.0042	CcSEcCtD
Pyrazinamide—Discomfort—Cisplatin—urinary bladder cancer	0.00038	0.00419	CcSEcCtD
Pyrazinamide—Anorexia—Gemcitabine—urinary bladder cancer	0.000377	0.00416	CcSEcCtD
Pyrazinamide—Urticaria—Thiotepa—urinary bladder cancer	0.000373	0.00412	CcSEcCtD
Pyrazinamide—Malaise—Etoposide—urinary bladder cancer	0.000373	0.00411	CcSEcCtD
Pyrazinamide—Body temperature increased—Thiotepa—urinary bladder cancer	0.000371	0.0041	CcSEcCtD
Pyrazinamide—Anorexia—Fluorouracil—urinary bladder cancer	0.00037	0.00409	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000367	0.00658	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000363	0.00653	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000361	0.00398	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00036	0.00397	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000354	0.00391	CcSEcCtD
Pyrazinamide—Anorexia—Cisplatin—urinary bladder cancer	0.000351	0.00387	CcSEcCtD
Pyrazinamide—Discomfort—Etoposide—urinary bladder cancer	0.000348	0.00384	CcSEcCtD
Pyrazinamide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000346	0.00382	CcSEcCtD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000346	0.00621	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000343	0.00379	CcSEcCtD
Pyrazinamide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000342	0.00377	CcSEcCtD
Pyrazinamide—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000341	0.00613	CbGpPWpGaD
Pyrazinamide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000341	0.00376	CcSEcCtD
Pyrazinamide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000338	0.00373	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000335	0.0037	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000335	0.0037	CcSEcCtD
Pyrazinamide—Dysuria—Methotrexate—urinary bladder cancer	0.000332	0.00367	CcSEcCtD
Pyrazinamide—Pruritus—Thiotepa—urinary bladder cancer	0.000332	0.00367	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00033	0.00365	CcSEcCtD
Pyrazinamide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000326	0.00359	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000324	0.00358	CcSEcCtD
Pyrazinamide—Anorexia—Etoposide—urinary bladder cancer	0.000322	0.00355	CcSEcCtD
Pyrazinamide—Decreased appetite—Cisplatin—urinary bladder cancer	0.00032	0.00353	CcSEcCtD
Pyrazinamide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00032	0.00353	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000318	0.00351	CcSEcCtD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000316	0.00567	CbGpPWpGaD
Pyrazinamide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000312	0.00345	CcSEcCtD
Pyrazinamide—Dysuria—Epirubicin—urinary bladder cancer	0.000311	0.00343	CcSEcCtD
Pyrazinamide—Urticaria—Fluorouracil—urinary bladder cancer	0.000309	0.00341	CcSEcCtD
Pyrazinamide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000307	0.00339	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000304	0.00335	CcSEcCtD
Pyrazinamide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000303	0.00335	CcSEcCtD
Pyrazinamide—Vomiting—Thiotepa—urinary bladder cancer	0.000299	0.0033	CcSEcCtD
Pyrazinamide—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000298	0.00535	CbGpPWpGaD
Pyrazinamide—Rash—Thiotepa—urinary bladder cancer	0.000296	0.00327	CcSEcCtD
Pyrazinamide—Dermatitis—Thiotepa—urinary bladder cancer	0.000296	0.00327	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000295	0.0053	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Etoposide—urinary bladder cancer	0.000293	0.00324	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000291	0.00321	CcSEcCtD
Pyrazinamide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000291	0.00321	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000291	0.00522	CbGpPWpGaD
Pyrazinamide—Dysuria—Doxorubicin—urinary bladder cancer	0.000288	0.00318	CcSEcCtD
Pyrazinamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000286	0.00316	CcSEcCtD
Pyrazinamide—Hepatitis—Methotrexate—urinary bladder cancer	0.000284	0.00314	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000281	0.0031	CcSEcCtD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00028	0.00504	CbGpPWpGaD
Pyrazinamide—Pruritus—Gemcitabine—urinary bladder cancer	0.00028	0.00309	CcSEcCtD
Pyrazinamide—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000279	0.00502	CbGpPWpGaD
Pyrazinamide—Nausea—Thiotepa—urinary bladder cancer	0.000279	0.00308	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000278	0.00307	CcSEcCtD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000276	0.00496	CbGpPWpGaD
Pyrazinamide—Pruritus—Fluorouracil—urinary bladder cancer	0.000275	0.00303	CcSEcCtD
Pyrazinamide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000271	0.00299	CcSEcCtD
Pyrazinamide—Urticaria—Etoposide—urinary bladder cancer	0.000268	0.00296	CcSEcCtD
Pyrazinamide—Body temperature increased—Etoposide—urinary bladder cancer	0.000267	0.00294	CcSEcCtD
Pyrazinamide—Hepatitis—Epirubicin—urinary bladder cancer	0.000266	0.00294	CcSEcCtD
Pyrazinamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000251	0.00277	CcSEcCtD
Pyrazinamide—Rash—Gemcitabine—urinary bladder cancer	0.000249	0.00275	CcSEcCtD
Pyrazinamide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000249	0.00275	CcSEcCtD
Pyrazinamide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000249	0.00274	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000247	0.00444	CbGpPWpGaD
Pyrazinamide—Vomiting—Fluorouracil—urinary bladder cancer	0.000247	0.00273	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—urinary bladder cancer	0.000246	0.00272	CcSEcCtD
Pyrazinamide—Rash—Fluorouracil—urinary bladder cancer	0.000245	0.0027	CcSEcCtD
Pyrazinamide—AOX1—Disease—GSTO2—urinary bladder cancer	0.000245	0.0044	CbGpPWpGaD
Pyrazinamide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000245	0.0027	CcSEcCtD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000244	0.00438	CbGpPWpGaD
Pyrazinamide—Pruritus—Etoposide—urinary bladder cancer	0.000239	0.00263	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000238	0.00427	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000238	0.00427	CbGpPWpGaD
Pyrazinamide—Nausea—Gemcitabine—urinary bladder cancer	0.000235	0.00259	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000234	0.00421	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000234	0.00421	CbGpPWpGaD
Pyrazinamide—Vomiting—Cisplatin—urinary bladder cancer	0.000234	0.00258	CcSEcCtD
Pyrazinamide—Rash—Cisplatin—urinary bladder cancer	0.000232	0.00256	CcSEcCtD
Pyrazinamide—Dermatitis—Cisplatin—urinary bladder cancer	0.000232	0.00256	CcSEcCtD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000231	0.00415	CbGpPWpGaD
Pyrazinamide—Nausea—Fluorouracil—urinary bladder cancer	0.000231	0.00255	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00023	0.00254	CcSEcCtD
Pyrazinamide—Malaise—Methotrexate—urinary bladder cancer	0.000223	0.00246	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.00022	0.00394	CbGpPWpGaD
Pyrazinamide—Nausea—Cisplatin—urinary bladder cancer	0.000219	0.00241	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—GSTZ1—urinary bladder cancer	0.000216	0.00388	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000215	0.00237	CcSEcCtD
Pyrazinamide—Vomiting—Etoposide—urinary bladder cancer	0.000214	0.00237	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000214	0.00385	CbGpPWpGaD
Pyrazinamide—Rash—Etoposide—urinary bladder cancer	0.000213	0.00235	CcSEcCtD
Pyrazinamide—Dermatitis—Etoposide—urinary bladder cancer	0.000213	0.00235	CcSEcCtD
Pyrazinamide—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000211	0.0038	CbGpPWpGaD
Pyrazinamide—Arthralgia—Methotrexate—urinary bladder cancer	0.000211	0.00233	CcSEcCtD
Pyrazinamide—Myalgia—Methotrexate—urinary bladder cancer	0.000211	0.00233	CcSEcCtD
Pyrazinamide—Malaise—Epirubicin—urinary bladder cancer	0.000209	0.00231	CcSEcCtD
Pyrazinamide—Discomfort—Methotrexate—urinary bladder cancer	0.000208	0.0023	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—NAT1—urinary bladder cancer	0.000205	0.00368	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTO2—urinary bladder cancer	0.000205	0.00368	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTZ1—urinary bladder cancer	0.000201	0.00361	CbGpPWpGaD
Pyrazinamide—Nausea—Etoposide—urinary bladder cancer	0.0002	0.00221	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000199	0.0022	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000198	0.00218	CcSEcCtD
Pyrazinamide—Myalgia—Epirubicin—urinary bladder cancer	0.000197	0.00218	CcSEcCtD
Pyrazinamide—Arthralgia—Epirubicin—urinary bladder cancer	0.000197	0.00218	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000196	0.00352	CbGpPWpGaD
Pyrazinamide—Discomfort—Epirubicin—urinary bladder cancer	0.000195	0.00215	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—urinary bladder cancer	0.000193	0.00213	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000193	0.00347	CbGpPWpGaD
Pyrazinamide—Anorexia—Methotrexate—urinary bladder cancer	0.000193	0.00213	CcSEcCtD
Pyrazinamide—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000191	0.00343	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTO2—urinary bladder cancer	0.000191	0.00342	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—NAT1—urinary bladder cancer	0.000191	0.00342	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00019	0.00342	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SLC19A1—urinary bladder cancer	0.00019	0.00342	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000188	0.00338	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—UGT2B7—urinary bladder cancer	0.000188	0.00337	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PRSS3—urinary bladder cancer	0.000186	0.00333	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000185	0.00204	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000184	0.00203	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—urinary bladder cancer	0.000183	0.00201	CcSEcCtD
Pyrazinamide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000183	0.00201	CcSEcCtD
Pyrazinamide—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000181	0.00325	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000181	0.00325	CbGpPWpGaD
Pyrazinamide—Discomfort—Doxorubicin—urinary bladder cancer	0.00018	0.00199	CcSEcCtD
Pyrazinamide—Anorexia—Epirubicin—urinary bladder cancer	0.00018	0.00199	CcSEcCtD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000178	0.00321	CbGpPWpGaD
Pyrazinamide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000178	0.00196	CcSEcCtD
Pyrazinamide—AOX1—Disease—HDAC4—urinary bladder cancer	0.000177	0.00318	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000176	0.00194	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000176	0.00315	CbGpPWpGaD
Pyrazinamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000174	0.00193	CcSEcCtD
Pyrazinamide—XDH—Metabolism—UGT2B7—urinary bladder cancer	0.000174	0.00313	CbGpPWpGaD
Pyrazinamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000172	0.0019	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000171	0.00189	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.00017	0.00306	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CYP4B1—urinary bladder cancer	0.000169	0.00303	CbGpPWpGaD
Pyrazinamide—Anorexia—Doxorubicin—urinary bladder cancer	0.000167	0.00184	CcSEcCtD
Pyrazinamide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000167	0.00184	CcSEcCtD
Pyrazinamide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000166	0.00184	CcSEcCtD
Pyrazinamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000166	0.00299	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000165	0.00297	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000164	0.00181	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000163	0.0018	CcSEcCtD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000163	0.00293	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000163	0.00293	CbGpPWpGaD
Pyrazinamide—Urticaria—Methotrexate—urinary bladder cancer	0.000161	0.00177	CcSEcCtD
Pyrazinamide—Body temperature increased—Methotrexate—urinary bladder cancer	0.00016	0.00176	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—SLC19A1—urinary bladder cancer	0.000159	0.00286	CbGpPWpGaD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000159	0.00176	CcSEcCtD
Pyrazinamide—XDH—Metabolism—CYP4B1—urinary bladder cancer	0.000157	0.00282	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000156	0.00172	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—PRSS3—urinary bladder cancer	0.000155	0.00279	CbGpPWpGaD
Pyrazinamide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000154	0.0017	CcSEcCtD
Pyrazinamide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000152	0.00168	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000151	0.00167	CcSEcCtD
Pyrazinamide—Urticaria—Epirubicin—urinary bladder cancer	0.00015	0.00166	CcSEcCtD
Pyrazinamide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000149	0.00165	CcSEcCtD
Pyrazinamide—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000149	0.00268	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000149	0.00164	CcSEcCtD
Pyrazinamide—XDH—Metabolism—SLC19A1—urinary bladder cancer	0.000148	0.00266	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000147	0.00264	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PRSS3—urinary bladder cancer	0.000144	0.00259	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000144	0.00159	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000143	0.00257	CbGpPWpGaD
Pyrazinamide—Pruritus—Methotrexate—urinary bladder cancer	0.000143	0.00158	CcSEcCtD
Pyrazinamide—AOX1—Disease—LIG1—urinary bladder cancer	0.000141	0.00253	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000139	0.00154	CcSEcCtD
Pyrazinamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000139	0.00153	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000138	0.00153	CcSEcCtD
Pyrazinamide—Pruritus—Epirubicin—urinary bladder cancer	0.000134	0.00148	CcSEcCtD
Pyrazinamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000129	0.00142	CcSEcCtD
Pyrazinamide—Vomiting—Methotrexate—urinary bladder cancer	0.000128	0.00142	CcSEcCtD
Pyrazinamide—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000128	0.00231	CbGpPWpGaD
Pyrazinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000128	0.00231	CbGpPWpGaD
Pyrazinamide—Rash—Methotrexate—urinary bladder cancer	0.000127	0.00141	CcSEcCtD
Pyrazinamide—Dermatitis—Methotrexate—urinary bladder cancer	0.000127	0.0014	CcSEcCtD
Pyrazinamide—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000127	0.00228	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000125	0.00224	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—TYMP—urinary bladder cancer	0.000124	0.00223	CbGpPWpGaD
Pyrazinamide—Pruritus—Doxorubicin—urinary bladder cancer	0.000124	0.00137	CcSEcCtD
Pyrazinamide—Vomiting—Epirubicin—urinary bladder cancer	0.00012	0.00133	CcSEcCtD
Pyrazinamide—Nausea—Methotrexate—urinary bladder cancer	0.00012	0.00132	CcSEcCtD
Pyrazinamide—Rash—Epirubicin—urinary bladder cancer	0.000119	0.00132	CcSEcCtD
Pyrazinamide—Dermatitis—Epirubicin—urinary bladder cancer	0.000119	0.00131	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000118	0.00212	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—TYMP—urinary bladder cancer	0.000115	0.00207	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—NAT2—urinary bladder cancer	0.000112	0.00202	CbGpPWpGaD
Pyrazinamide—Nausea—Epirubicin—urinary bladder cancer	0.000112	0.00124	CcSEcCtD
Pyrazinamide—Vomiting—Doxorubicin—urinary bladder cancer	0.000111	0.00123	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—urinary bladder cancer	0.00011	0.00122	CcSEcCtD
Pyrazinamide—Dermatitis—Doxorubicin—urinary bladder cancer	0.00011	0.00122	CcSEcCtD
Pyrazinamide—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000108	0.00195	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ENO2—urinary bladder cancer	0.000107	0.00193	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—NAT2—urinary bladder cancer	0.000104	0.00188	CbGpPWpGaD
Pyrazinamide—Nausea—Doxorubicin—urinary bladder cancer	0.000104	0.00115	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000103	0.00185	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000103	0.00184	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—RBX1—urinary bladder cancer	0.000102	0.00183	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	9.96e-05	0.00179	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	9.91e-05	0.00178	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	9.78e-05	0.00176	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—RRM2—urinary bladder cancer	9.7e-05	0.00174	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	9.61e-05	0.00173	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	9.52e-05	0.00171	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—JAG1—urinary bladder cancer	9.1e-05	0.00163	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—RRM2—urinary bladder cancer	9.02e-05	0.00162	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—HPGDS—urinary bladder cancer	8.98e-05	0.00161	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ENO2—urinary bladder cancer	8.98e-05	0.00161	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	8.98e-05	0.00161	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTT1—urinary bladder cancer	8.71e-05	0.00156	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	8.54e-05	0.00153	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	8.54e-05	0.00153	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ENO2—urinary bladder cancer	8.35e-05	0.0015	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—HPGDS—urinary bladder cancer	8.35e-05	0.0015	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	8.31e-05	0.00149	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	8.31e-05	0.00149	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTT1—urinary bladder cancer	8.1e-05	0.00145	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	7.93e-05	0.00142	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	7.69e-05	0.00138	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	7.44e-05	0.00134	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.41e-05	0.00133	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.28e-05	0.00131	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	7.28e-05	0.00131	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—NQO1—urinary bladder cancer	7.24e-05	0.0013	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	6.93e-05	0.00125	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	6.93e-05	0.00125	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	6.9e-05	0.00124	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	6.88e-05	0.00124	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.81e-05	0.00122	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—NQO1—urinary bladder cancer	6.73e-05	0.00121	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—NCOR1—urinary bladder cancer	6.63e-05	0.00119	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	6.34e-05	0.00114	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.26e-05	0.00112	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ERCC2—urinary bladder cancer	6.23e-05	0.00112	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTP1—urinary bladder cancer	6.04e-05	0.00108	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MTHFR—urinary bladder cancer	5.86e-05	0.00105	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	5.85e-05	0.00105	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TERT—urinary bladder cancer	5.84e-05	0.00105	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—TYMS—urinary bladder cancer	5.61e-05	0.00101	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTP1—urinary bladder cancer	5.61e-05	0.00101	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GSTM1—urinary bladder cancer	5.55e-05	0.000997	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—NCOR1—urinary bladder cancer	5.55e-05	0.000997	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—FGFR3—urinary bladder cancer	5.36e-05	0.000962	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.33e-05	0.000957	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GPX1—urinary bladder cancer	5.31e-05	0.000954	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.25e-05	0.000944	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—TYMS—urinary bladder cancer	5.22e-05	0.000937	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ERCC2—urinary bladder cancer	5.22e-05	0.000937	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GSTM1—urinary bladder cancer	5.16e-05	0.000927	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—NCOR1—urinary bladder cancer	5.16e-05	0.000927	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GPX1—urinary bladder cancer	4.94e-05	0.000887	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—MTHFR—urinary bladder cancer	4.9e-05	0.000881	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.9e-05	0.000879	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ERCC2—urinary bladder cancer	4.85e-05	0.000871	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.83e-05	0.000867	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CREBBP—urinary bladder cancer	4.56e-05	0.000819	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—MTHFR—urinary bladder cancer	4.56e-05	0.000819	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.23e-05	0.00076	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—RHOA—urinary bladder cancer	4.13e-05	0.000741	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.01e-05	0.00072	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.01e-05	0.00072	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PPARG—urinary bladder cancer	3.98e-05	0.000714	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.94e-05	0.000708	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CREBBP—urinary bladder cancer	3.82e-05	0.000686	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ERBB2—urinary bladder cancer	3.82e-05	0.000686	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTGS2—urinary bladder cancer	3.73e-05	0.000671	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PPARG—urinary bladder cancer	3.7e-05	0.000664	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.67e-05	0.000659	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CREBBP—urinary bladder cancer	3.55e-05	0.000638	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.3e-05	0.000593	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CDKN1A—urinary bladder cancer	3.26e-05	0.000586	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.26e-05	0.000586	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTEN—urinary bladder cancer	3.26e-05	0.000585	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTGS2—urinary bladder cancer	3.13e-05	0.000562	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.12e-05	0.00056	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—EP300—urinary bladder cancer	3.11e-05	0.000558	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.09e-05	0.000556	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.09e-05	0.000556	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.04e-05	0.000546	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SRC—urinary bladder cancer	3.02e-05	0.000543	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTGS2—urinary bladder cancer	2.91e-05	0.000522	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.83e-05	0.000508	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTEN—urinary bladder cancer	2.73e-05	0.00049	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MYC—urinary bladder cancer	2.71e-05	0.000486	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—EGFR—urinary bladder cancer	2.65e-05	0.000476	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—EP300—urinary bladder cancer	2.6e-05	0.000467	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.55e-05	0.000458	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTEN—urinary bladder cancer	2.54e-05	0.000456	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—KRAS—urinary bladder cancer	2.5e-05	0.000449	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.44e-05	0.000438	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.43e-05	0.000436	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—EP300—urinary bladder cancer	2.42e-05	0.000434	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.41e-05	0.000432	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.34e-05	0.000421	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.33e-05	0.000419	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.2e-05	0.000395	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—HRAS—urinary bladder cancer	2.13e-05	0.000382	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.9e-05	0.000341	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.87e-05	0.000337	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.76e-05	0.000315	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.76e-05	0.000315	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.75e-05	0.000314	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.7e-05	0.000306	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.7e-05	0.000305	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.68e-05	0.000301	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.46e-05	0.000263	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.42e-05	0.000254	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.37e-05	0.000247	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.36e-05	0.000243	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.36e-05	0.000243	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.31e-05	0.000236	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.2e-05	0.000215	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.18e-05	0.000212	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.14e-05	0.000205	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.1e-05	0.000197	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.09e-05	0.000196	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.08e-05	0.000195	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.08e-05	0.000195	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.04e-05	0.000187	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	0.000183	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.59e-06	0.000172	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.11e-06	0.000164	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.47e-06	0.000152	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.37e-06	0.00015	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.37e-06	0.00015	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.02e-06	0.000144	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.87e-06	0.000141	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.78e-06	0.00014	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.47e-06	0.000134	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.4e-06	0.000133	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.12e-06	0.00011	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6e-06	0.000108	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.76e-06	0.000104	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.33e-06	9.58e-05	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.09e-06	9.14e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.72e-06	8.48e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.12e-06	7.39e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.93e-06	7.05e-05	CbGpPWpGaD
